BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dibba P, Li AA, Cholankeril G, Iqbal U, Gadiparthi C, Khan MA, Kim D, Ahmed A. The Role of Cannabinoids in the Setting of Cirrhosis. Medicines (Basel). 2018;5. [PMID: 29890719 DOI: 10.3390/medicines5020052] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Griffett K, Hayes ME, Boeckman MP, Burris TP. The role of REV-ERB in NASH. Acta Pharmacol Sin 2022. [PMID: 35217816 DOI: 10.1038/s41401-022-00883-w] [Reference Citation Analysis]
2 Whitfield JB, Masson S, Liangpunsakul S, Mueller S, Aithal GP, Eyer F, Gleeson D, Thompson A, Stickel F, Soyka M, Muellhaupt B, Daly AK, Cordell HJ, Foroud T, Lumeng L, Pirmohamed M, Nalpas B, Jacquet JM, Moirand R, Nahon P, Naveau S, Perney P, Haber PS, Seitz HK, Day CP, Mathurin P, Morgan TR, Seth D; GenomALC Consortium. Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. Am J Gastroenterol 2021;116:106-15. [PMID: 32868629 DOI: 10.14309/ajg.0000000000000833] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
3 Hashiesh HM, Sharma C, Goyal SN, Jha NK, Ojha S. Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist. Front Pharmacol 2021;12:702675. [PMID: 34393784 DOI: 10.3389/fphar.2021.702675] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Issa YA, El Achy SN, Mady RF. Cannabinoid receptor-1 antagonism: a new perspective on treating a murine schistosomal liver fibrosis model. Mem Inst Oswaldo Cruz 2019;114:e190062. [PMID: 31389521 DOI: 10.1590/0074-02760190062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
5 Sobotka LA, Mumtaz K, Hinton A, Kelly SG, Conteh LF, Michaels AJ, Hanje AJ, Wellner MR. Cannabis use may reduce healthcare utilization and improve hospital outcomes in patients with cirrhosis. Ann Hepatol 2021;23:100280. [PMID: 33157269 DOI: 10.1016/j.aohep.2020.10.008] [Reference Citation Analysis]
6 Melgar-Lesmes P, Perramon M, Jiménez W. Roles of the Hepatic Endocannabinoid and Apelin Systems in the Pathogenesis of Liver Fibrosis. Cells 2019;8:E1311. [PMID: 31653030 DOI: 10.3390/cells8111311] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
7 Berk K, Bzdega W, Konstantynowicz-Nowicka K, Charytoniuk T, Zywno H, Chabowski A. Phytocannabinoids-A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment. J Clin Med 2021;10:393. [PMID: 33498537 DOI: 10.3390/jcm10030393] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ahmed I, Rehman SU, Shahmohamadnejad S, Zia MA, Ahmad M, Saeed MM, Akram Z, Iqbal HMN, Liu Q. Therapeutic Attributes of Endocannabinoid System against Neuro-Inflammatory Autoimmune Disorders. Molecules 2021;26:3389. [PMID: 34205169 DOI: 10.3390/molecules26113389] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Damiris K, Tafesh ZH, Pyrsopoulos N. Efficacy and safety of anti-hepatic fibrosis drugs. World J Gastroenterol 2020; 26(41): 6304-6321 [PMID: 33244194 DOI: 10.3748/wjg.v26.i41.6304] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
10 Killilea M, Kerr DM, Mallard BM, Roche M, Wheatley AM. Exacerbated LPS/GalN-Induced Liver Injury in the Stress-Sensitive Wistar Kyoto Rat Is Associated with Changes in the Endocannabinoid System. Molecules 2020;25:E3834. [PMID: 32842550 DOI: 10.3390/molecules25173834] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Perumpail BJ, Li AA, Iqbal U, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD. Diseases 2018;6:E80. [PMID: 30201879 DOI: 10.3390/diseases6030080] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]